BONORA, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 5.037
EU - Europa 2.261
AS - Asia 1.151
AF - Africa 216
SA - Sud America 163
OC - Oceania 63
Continente sconosciuto - Info sul continente non disponibili 11
Totale 8.902
Nazione #
US - Stati Uniti d'America 4.898
IT - Italia 817
CN - Cina 462
DE - Germania 358
FR - Francia 242
GB - Regno Unito 213
IN - India 140
VN - Vietnam 119
CA - Canada 100
JP - Giappone 93
ES - Italia 87
ZA - Sudafrica 85
KR - Corea 77
BR - Brasile 74
RU - Federazione Russa 69
AU - Australia 59
NL - Olanda 55
PL - Polonia 49
CZ - Repubblica Ceca 44
ID - Indonesia 44
AT - Austria 37
CH - Svizzera 36
IE - Irlanda 36
MX - Messico 33
RO - Romania 33
CO - Colombia 32
SE - Svezia 31
FI - Finlandia 30
NG - Nigeria 29
HK - Hong Kong 27
BE - Belgio 24
TH - Thailandia 24
UG - Uganda 24
IR - Iran 23
MY - Malesia 21
TW - Taiwan 21
PK - Pakistan 20
CL - Cile 19
TR - Turchia 18
AR - Argentina 17
IL - Israele 17
DK - Danimarca 16
PT - Portogallo 16
GR - Grecia 15
UA - Ucraina 15
ET - Etiopia 14
SG - Singapore 14
PE - Perù 13
KE - Kenya 11
TZ - Tanzania 9
EU - Europa 8
EG - Egitto 7
LT - Lituania 7
HR - Croazia 6
HU - Ungheria 6
PH - Filippine 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
MA - Marocco 5
VE - Venezuela 5
CM - Camerun 4
GH - Ghana 4
JO - Giordania 4
NZ - Nuova Zelanda 4
AL - Albania 3
CD - Congo 3
EE - Estonia 3
LU - Lussemburgo 3
MW - Malawi 3
PR - Porto Rico 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
A1 - Anonimo 2
BG - Bulgaria 2
EC - Ecuador 2
GA - Gabon 2
NO - Norvegia 2
QA - Qatar 2
YE - Yemen 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
BT - Bhutan 1
BW - Botswana 1
CI - Costa d'Avorio 1
CU - Cuba 1
CY - Cipro 1
GM - Gambi 1
GT - Guatemala 1
IQ - Iraq 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MZ - Mozambico 1
Totale 8.896
Città #
Fairfield 615
Houston 399
Woodbridge 328
Ashburn 326
Seattle 288
Torino 278
Santa Cruz 264
Buffalo 254
Ann Arbor 227
Wilmington 192
Beijing 190
Cambridge 189
Dong Ket 84
San Diego 76
Chicago 67
Turin 66
Los Angeles 57
University Park 56
Shanghai 54
Warsaw 45
Milan 42
Pisa 41
Mountain View 38
Las Vegas 36
Wuhan 36
Columbus 34
Ottawa 31
Dublin 28
Bengaluru 27
Chandler 27
Boardman 26
Vienna 26
Dallas 25
Phoenix 25
Rome 25
New York 24
Helsinki 21
Miami 21
Jakarta 20
Muizenberg 19
Nürnberg 19
São Paulo 19
Toronto 19
Clearwater 17
Guangzhou 17
Nanjing 17
Paris 17
Boston 16
San Francisco 16
Hangzhou 15
Leawood 15
Riva 15
Taipei 14
Baltimore 13
Lake Forest 13
Lima 13
Madrid 13
Padova 13
Provo 13
Changsha 12
Duncan 12
Henderson 12
San Jose 12
Bogotá 11
Council Bluffs 11
Guiyang 11
London 11
Santiago 11
Seoul 11
Tokyo 11
Vicenza 11
Washington 11
Central 10
Herndon 10
Melbourne 10
Mumbai 10
Amsterdam 9
Atlanta 9
Bucharest 9
Buenos Aires 9
Durban 9
Kuala Lumpur 9
Liverpool 9
Madison 9
Rochester 9
Saint Petersburg 9
Yokosuka 9
Birmingham 8
Bologna 8
Dearborn 8
Easton 8
Fleming Island 8
Gif-sur-yvette 8
Hyderabad 8
Louisville 8
Mexico 8
Toulouse 8
Woburn 8
Athens 7
Bangkok 7
Totale 5.309
Nome #
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system., file e27ce427-48e2-2581-e053-d805fe0acbaa 476
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era, file e27ce427-fa86-2581-e053-d805fe0acbaa 409
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis, file e27ce427-40cf-2581-e053-d805fe0acbaa 313
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?, file e27ce42d-83f8-2581-e053-d805fe0acbaa 313
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment., file e27ce426-edaf-2581-e053-d805fe0acbaa 290
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1., file e27ce426-fb81-2581-e053-d805fe0acbaa 281
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting, file e27ce426-c733-2581-e053-d805fe0acbaa 268
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs, file e27ce427-8c10-2581-e053-d805fe0acbaa 258
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients, file e27ce427-fa88-2581-e053-d805fe0acbaa 256
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment, file e27ce42e-dc35-2581-e053-d805fe0acbaa 246
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation, file e27ce42f-3070-2581-e053-d805fe0acbaa 244
Acute HIV infection: Improved algorithms for HIV testing., file e27ce427-f50f-2581-e053-d805fe0acbaa 217
Disappearance of Renal Stones in an HIV-1-Infected Patient After Reduction of Atazanavir Dose., file e27ce427-0fcf-2581-e053-d805fe0acbaa 216
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells., file e27ce42a-2054-2581-e053-d805fe0acbaa 187
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis., file e27ce426-fdb2-2581-e053-d805fe0acbaa 183
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors., file e27ce42a-3e63-2581-e053-d805fe0acbaa 172
Cardiovascular disease in HIV patients: from bench to bedside and backwards, file e27ce427-460c-2581-e053-d805fe0acbaa 169
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations., file e27ce426-dd32-2581-e053-d805fe0acbaa 167
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV, file e27ce430-6596-2581-e053-d805fe0acbaa 160
Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV., file e27ce429-0c12-2581-e053-d805fe0acbaa 149
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014, file e27ce427-f7f3-2581-e053-d805fe0acbaa 146
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome, file e27ce427-0c1c-2581-e053-d805fe0acbaa 139
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity, file e27ce431-c41d-2581-e053-d805fe0acbaa 139
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy, file e27ce428-b03e-2581-e053-d805fe0acbaa 138
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV, file e27ce42d-d3c3-2581-e053-d805fe0acbaa 136
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients., file e27ce429-063f-2581-e053-d805fe0acbaa 132
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients, file e27ce429-b6a7-2581-e053-d805fe0acbaa 131
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study), file e27ce427-493f-2581-e053-d805fe0acbaa 128
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort, file e27ce429-a93c-2581-e053-d805fe0acbaa 128
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus, file e27ce429-bd05-2581-e053-d805fe0acbaa 124
Blood–brain barrier impairment in patients living with hiv: Predictors and associated biomarkers, file e27ce432-7a78-2581-e053-d805fe0acbaa 122
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients., file e27ce426-f675-2581-e053-d805fe0acbaa 121
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study, file e27ce42d-649a-2581-e053-d805fe0acbaa 115
Prevalence and predictors of blood-brain barrier damage in the HAART era., file e27ce428-ccd6-2581-e053-d805fe0acbaa 106
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study, file e27ce42a-5f2a-2581-e053-d805fe0acbaa 99
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort, file e27ce42d-d3bf-2581-e053-d805fe0acbaa 98
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS, file e27ce429-0fa8-2581-e053-d805fe0acbaa 96
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage., file e27ce426-d682-2581-e053-d805fe0acbaa 94
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis, file e27ce42d-c454-2581-e053-d805fe0acbaa 94
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy, file e27ce42e-fdc1-2581-e053-d805fe0acbaa 94
Co-infection with other respiratory pathogens in COVID-19 patients, file e27ce431-c341-2581-e053-d805fe0acbaa 92
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment, file e27ce42c-7f76-2581-e053-d805fe0acbaa 83
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection, file e27ce432-0f19-2581-e053-d805fe0acbaa 72
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42e-f730-2581-e053-d805fe0acbaa 69
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV, file e27ce431-312c-2581-e053-d805fe0acbaa 67
Heart failure in patients with human immunodeficiency virus: a review of the literature., file e27ce428-cee3-2581-e053-d805fe0acbaa 65
Raltegravir penetration in seminal plasma of healthy volunteers., file e27ce426-cc1e-2581-e053-d805fe0acbaa 64
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project, file e27ce427-f7f1-2581-e053-d805fe0acbaa 64
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients, file e27ce432-27ed-2581-e053-d805fe0acbaa 62
What do we know about tailoring treatment with tenofovir?, file e27ce429-0a6b-2581-e053-d805fe0acbaa 61
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment, file e27ce429-b2bb-2581-e053-d805fe0acbaa 61
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia, file e27ce42d-7235-2581-e053-d805fe0acbaa 55
The manifesto of pharmacoenosis: Merging hiv pharmacology into pathocoenosis and syndemics in developing countries, file e27ce433-32b1-2581-e053-d805fe0acbaa 53
Clinical phenotype and contagiousness of early breakthrough SARS-CoV-2 infections after BNT162b2 COVID-19 mRNA vaccine: A parallel cohort study in healthcare workers, file e27ce434-8c4d-2581-e053-d805fe0acbaa 50
Class-specific relative genetic contribution for key antiretroviral drugs, file e27ce42a-686a-2581-e053-d805fe0acbaa 49
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?, file e27ce42d-33fb-2581-e053-d805fe0acbaa 49
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening, file e27ce431-e772-2581-e053-d805fe0acbaa 48
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control., file e27ce42a-5667-2581-e053-d805fe0acbaa 45
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs, file e27ce42a-6e2f-2581-e053-d805fe0acbaa 45
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy, file e27ce432-7646-2581-e053-d805fe0acbaa 43
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma, file e27ce431-d047-2581-e053-d805fe0acbaa 42
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases, file e27ce432-218f-2581-e053-d805fe0acbaa 41
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients, file e27ce42f-7b61-2581-e053-d805fe0acbaa 36
Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition, file e27ce435-6124-2581-e053-d805fe0acbaa 36
Bosentan and Fosamprenavir: an effective and safe combination in an HIV-infected patient with pulmonary arterial hypertension, file e27ce428-a634-2581-e053-d805fe0acbaa 35
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms., file e27ce42a-40fa-2581-e053-d805fe0acbaa 33
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring, file e27ce435-8569-2581-e053-d805fe0acbaa 30
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV, file e27ce435-810a-2581-e053-d805fe0acbaa 27
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders, file e27ce42d-6343-2581-e053-d805fe0acbaa 26
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients., file e27ce42a-195b-2581-e053-d805fe0acbaa 24
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting, file e27ce42a-e313-2581-e053-d805fe0acbaa 24
Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis, file e27ce42a-e856-2581-e053-d805fe0acbaa 23
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING, file e27ce426-d012-2581-e053-d805fe0acbaa 22
Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections, file cf3e873d-3056-45c4-b40f-a348fd009f60 18
Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants, file 571f5786-874f-469d-a28a-706129d78ea1 16
Treating HIV Infection in the Central Nervous System, file e27ce42a-bc75-2581-e053-d805fe0acbaa 16
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment., file e27ce426-eb1c-2581-e053-d805fe0acbaa 15
On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases, file e27ce432-0f73-2581-e053-d805fe0acbaa 15
Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients, file e27ce427-f671-2581-e053-d805fe0acbaa 14
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis, file e27ce434-68d1-2581-e053-d805fe0acbaa 12
BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors, file b7f32c09-d21d-4ed8-afc9-9acfed502ba4 11
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose, file d4de2785-4f79-438d-a6f2-10c847df20d5 11
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42c-accc-2581-e053-d805fe0acbaa 11
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV, file e27ce433-22d2-2581-e053-d805fe0acbaa 11
Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases, file e27ce435-6126-2581-e053-d805fe0acbaa 11
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing, file e27ce42a-683f-2581-e053-d805fe0acbaa 10
Enhancing care for people living with HIV: current and future monitoring approaches, file e27ce432-5ef6-2581-e053-d805fe0acbaa 10
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment, file e27ce429-b616-2581-e053-d805fe0acbaa 9
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration, file e27ce42e-f8ce-2581-e053-d805fe0acbaa 8
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial, file e27ce430-ae1f-2581-e053-d805fe0acbaa 8
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring, file e27ce432-90a4-2581-e053-d805fe0acbaa 8
Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia, file 1ffebb63-cb7b-46b1-acb4-9f84ca8edd63 7
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42c-9d4e-2581-e053-d805fe0acbaa 7
A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues, file 28ef6e89-e184-4891-b06e-f8e817f43700 6
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen, file 33cf5bc9-54fe-4aac-9ef8-0a0261d15297 6
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study, file 4e1c1b47-d664-43a0-88b1-5ce013526ec1 6
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control., file e27ce428-c2c0-2581-e053-d805fe0acbaa 6
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS, file e27ce429-0fa7-2581-e053-d805fe0acbaa 6
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting, file 0d6bcdd6-db3a-4898-9375-1fa250c44d79 5
Cerebrospinal Fluid CXCL13 as Candidate Biomarker of Intrathecal Immune Activation, IgG Synthesis and Neurocognitive Impairment in People with HIV, file 861b61ad-deb3-4589-8c7b-4a7850d2b505 5
Totale 9.218
Categoria #
all - tutte 14.120
article - articoli 0
book - libri 0
conference - conferenze 45
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.165


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019515 0 0 0 0 0 0 0 0 0 0 289 226
2019/20201.721 170 126 91 251 138 123 135 180 168 127 97 115
2020/20211.510 79 108 75 64 163 171 100 131 103 175 133 208
2021/20221.982 223 130 141 276 202 95 113 106 113 97 343 143
2022/20231.455 66 120 326 218 99 122 92 121 123 64 87 17
2023/2024453 15 26 55 22 41 37 77 86 16 29 49 0
Totale 9.370